People
Aphria Inc. President, Jakob Ripshtein, is proposed to replace Mr Battersby as Non-Executive Director (pending ODC approval)
Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
In February, Galapagos NV Chief Executive Officer Onno van de Stolpe promised that 2019 will be a “data rich year” for the Belgium-based company and its lead product, filgotinib.
Alex Trebek, 78, host of TV game show “Jeopardy” announced yesterday that he had been diagnosed with stage 4 pancreatic cancer.
For more than a year, it had no name other than “ABC,” the first letters of each company’s name. Now, more than a year later, the endeavor has an official name, Haven.
Gottlieb announced his intention to leave the FDA earlier this week. The Trump administration will have a list of candidates to choose from as it moves forward.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
Scott Gottlieb, the proactive commissioner of the U.S. Food and Drug Administration has resigned, according to reports. Gottlieb will leave the regulatory agency in about a month.
PRESS RELEASES